Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells

Clinical Cancer Research

Volumn 18, Issue 3, 2012, Pages 726-736

  Wan, Xinhai ^a   Liu, Jie ^a,e   Lu, Jing Fang ^a   Tzelepi, Vassiliki ^a,b   Yang, Jun ^a   Starbuck, Michael W ^a   Diao, Lixia ^a   Wang, Jing ^a   Efstathiou, Eleni ^a,c   Vazquez, Elba S ^d   Troncoso, Patricia ^a   Maity, Sankar N ^a   Navone, Nora M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^e ST MARY S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; HYALURONIC ACID; WNT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE SEQUENCE; GENE SILENCING; HAS2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; BONE NEOPLASMS; GENE EXPRESSION PROFILING; GLUCURONOSYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; MUTATION; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84863011082     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2521     Document Type: Article

References (40)

1. Burd CJ, Morey LM, Knudsen KE. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer 2006;13:979-94. (Pubitemid 46212560)
2. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010;120:2715-30.
3. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010;107:16759-65.
4. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008;118:2697-710.
5. The Wnt home page. Wnt target genes. Stanford: 1997-2010 Roel Nusse. [cited 2010 Oct]. Available from: http://www.stanford.edu/ group/nusselab/cgi- bin/wnt/target-genes.
6. Yochum GS, McWeeney S, Rajaraman V, Cleland R, Peters S, Goodman RH. Serial analysis of chromatin occupancy identifies betacatenin target genes in colorectal carcinoma cells. Proc Natl Acad Sci U S A 2007;104:3324-9. (Pubitemid 46364158)
7. van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 2003; 13:28-33. (Pubitemid 36143924)
8. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, et al. XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos. Cell 1996; 86:391-9. (Pubitemid 26272079)
9. van de Wetering M, Cavallo R, Dooijes D, van Beest M, van Es J, Loureiro J, et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 1997;88: 789-99. (Pubitemid 27164267)
10. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of b-catenin with the transcription factor LEF-1. Nature 1996;382:638-42. (Pubitemid 26268958)
11. He T-C, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-12. (Pubitemid 28425575)
12. Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6. (Pubitemid 29180374)
13. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear β-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002;21:2679-94. (Pubitemid 34478326)
14. de la Taille A, Rubin MA, Chen M-W, Vacherot F, de Medina SG, Burchardt M, et al. β-Catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003;9:1801-7. (Pubitemid 36554607)
15. Yardy GW, Brewster SF. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis 2005;8:119-26. (Pubitemid 43118074)
16. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011;30:1868-79.
17. Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM, et al. Activation of β-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 2009;69:249-62.
18. Terry S, Yang X, Chen M-W, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006;99: 402-10. (Pubitemid 44435558)
19. Verras M, Sun Z. Roles and regulation of Wnt signaling and β-catenin in prostate cancer. Cancer Lett 2006;237:22-32.
20. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 1997;3:2493-500. (Pubitemid 28133173)
21. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7. (Pubitemid 27136714)
22. Al-Fageeh M, Li Q, Dashwood WM, Myzak MC, Dashwood RH. Phosphorylation and ubiquitination of oncogenic mutants of β-catenin containing substitutions at Asp32. Oncogene 2004;23:4839-46. (Pubitemid 38932156)
23. Provost E, McCabe A, Stern J, Lizardi I, D'Aquila TG, Rimm DL. Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin. Oncogene 2005;24:2667-76. (Pubitemid 40593094)
24. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB. Detection and analysis of β-catenin mutations in prostate cancer. Prostate 2000;45:323-34.
25. Fuerer C, Nusse R, Ten Berge D. Wnt signalling in development and disease. Max Delbrück Center for Molecular Medicine meeting on Wnt Signaling in Development and Disease. EMBO Rep 2008;9: 134-8. (Pubitemid 351223449)
26. Viola M, Vigetti D, Genasetti A, Rizzi M, Karousou E, Moretto P, et al. Molecular control of the hyaluronan biosynthesis. Connect Tissue Res 2008;49:111-4.
27. Jho E-H, Zhang T, Domon C, Joo C-K, Freund J-N, Costantini F. Wnt/ β-Catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002;22:1172-83. (Pubitemid 34094853)
28. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, et al. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002;22:1184-93. (Pubitemid 34094854)
29. Gomez CS, Gomez P, Knapp J, Jorda M, Soloway MS, Lokeshwar VB. Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol 2009;182:1350-6.
30. Bharadwaj AG, Kovar JL, Loughman E, Elowsky C, Oakley GG, Simpson MA. Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing. Am J Pathol 2009;174:1027-36.
31. Simpson MA. Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am J Pathol 2006;169:247-57.
32. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007;23:435-61.
33. Zoltan-Jones A, Huang L, Ghatak S, Toole BP. Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem 2003;278:45801-10. (Pubitemid 37432725)
34. Clevers H. Wnt/b-Catenin signaling in development and disease. Cell 2006;127:469-80.
35. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a β-TrCP1-Skp1-β-catenin complex: destruction motif binding and lysine specificity of the SCFβ-TrCP1 ubiquitin ligase. Mol Cell 2003;11:1445-56. (Pubitemid 36776532)
36. Voeller HJ, Truica CI, Gelmann EP. β-Catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-3. (Pubitemid 28275418)
37. Gerstein AV, Almeida TA, Zhao G, Chess E, Shih l-M, Buhler K, et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer 2002;34: 9-16. (Pubitemid 34260591)
38. Eger A, Stockinger A, Schaffhauser B, Beug H, Foisner R. Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of β-catenin and upregulation of β-catenin/ lymphoid enhancer binding factor-1 transcriptional activity. J Cell Biol 2000;148:173-88.
39. Li J, Zhou BP. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 2011;11:49.
40. Zhu ML, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010;24:769-77.